Effects of propofol on the expression of matric metalloproteinases in rat cardiac fibroblasts after hypoxia and reoxygenation

British Journal of Anaesthesia

Volumn 106, Issue 5, 2011, Pages 650-658

  Jun, J H ^a,b   Cho, J E ^a,b   Shim, Y H ^a,b   Shim, J K ^a,b   Kwak, Y L ^a,b  

^a Yonsei University College of Medicine   (South Korea)

^b Anaesthesia and Pain Research Institute   (South Korea)

Author keywords

ischaemia reperfusion; matrix metalloproteinases; propofol

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PROPOFOL; TISSUE INHIBITOR OF METALLOPROTEINASE; UO 126;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL ACTIVITY; CELL HYPOXIA; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; DRUG EFFECT; ENZYME BLOOD LEVEL; ENZYME PHOSPHORYLATION; FIBROBLAST; HEART MUSCLE CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RAT; REOXYGENATION; SIGNAL TRANSDUCTION; WOUND HEALING;

EID: 79954530074     PISSN: 00070912     EISSN: 14716771     Source Type: Journal    
DOI: 10.1093/bja/aer006     Document Type: Article

References (40)

1. Nagase H, Woessner JF Jr. Matrix metalloproteinases. J Biol Chem 1999; 274: 21491-4
2. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001; 17: 463-516 (Pubitemid 33096184)
3. Gomez DE, Alonso DF, Yoshiji H, Thorgeirsson UP. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol 1997; 74: 111-22 (Pubitemid 27455388)
4. Brew K, Dinakarpandian D, Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta 2000; 1477: 267-83 (Pubitemid 30119906)
5. Brown RD, Ambler SK, Mitchell MD, Long CS. The cardiac fibroblast: therapeutic target in myocardial remodeling and failure. Annu Rev Pharmacol Toxicol 2005; 45: 657-87 (Pubitemid 40261821)
6. Frangogiannis NG, Smith CW, Entman ML. The inflammatory response in myocardial infarction. Cardiovasc Res 2002; 53: 31-47 (Pubitemid 34020764)
7. Creemers EE, Cleutjens JP, Smits JF, Daemen MJ. Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure? Circ Res 2001; 89: 201-10 (Pubitemid 34132679)
8. Spinale FG. Matrix metalloproteinases: regulation and dysregulation in the failing heart. Circ Res 2002; 90: 520-30 (Pubitemid 34640901)
9. Stapel H, Kim SC, Osterkamp S, et al. Toll-like receptor 4 modulates myocardial ischaemia-reperfusion injury: role of matrix metalloproteinases. Eur J Heart Fail 2006; 8: 665-72 (Pubitemid 44635319)
10. Huang C, Jacobson K, Schaller MD. MAP kinases and cell migration. J Cell Sci 2004; 117: 4619-28 (Pubitemid 39433429)
11. Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002; 296: 1655-7 (Pubitemid 34579158)
12. Cho A, Graves J, Reidy MA. Mitogen-activated protein kinases mediate matrix metalloproteinase-9 expression in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2000; 20: 2527-32
13. Jugdutt BI. Remodeling of the myocardium and potential targets in the collagen degradation and synthesis pathways. Curr Drug Targets Cardiovasc Haematol Disord 2003; 3: 1-30 (Pubitemid 36244902)
14. Peng Z, Luo M, Ye S, et al. Antioxidative and anti-endotoxin effects of propofol on endothelial cells. Chin Med J (Engl) 2003; 116: 731-5 (Pubitemid 36701859)
15. McDermott BJ, McWilliams S, Smyth K, et al. Protection of cardiomyocyte function by propofol during simulated ischemia is associated with a direct action to reduce pro-oxidant activity. J Mol Cell Cardiol 2007; 42: 600-8 (Pubitemid 46350879)
16. Wang HY, Wang GL, Yu YH, Wang Y. The role of phosphoinositide-3-kinase/ Akt pathway in propofol-induced postconditioning against focal cerebral ischemia-reperfusion injury in rats. Brain Res 2009; 1297: 177-84
17. Kidambi S, Yarmush J, Fong W, Kamath S, Schianodicola J, Nahmias Y. Propofol induces ERK-dependant expression of c-Fos and Egr-1 in neuronal cells. Neuroreport 2009; 20: 657-62
18. Zou XJ, Yang L, Yao SL. Propofol depresses angiotensin II-induced cardiomyocyte hypertrophy in vitro. Exp Biol Med (Maywood) 2008; 233: 200-8 (Pubitemid 351231552)
19. Long CS, Henrich CJ, Simpson PC. A growth factor for cardiac myocytes is produced by cardiac nonmyocytes. Cell Regul 1991; 2: 1081-95
20. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986; 74: 1124-36 (Pubitemid 17174962)
21. Anaya-Prado R, Toledo-Pereyra LH. The molecular events underlying ischemia/reperfusion injury. Transplant Proc 2002; 34: 2518-9 (Pubitemid 35304817)
22. Tanaka K, Ludwig LM, Kersten JR, Pagel PS, Warltier DC. Mechanisms of cardioprotection by volatile anesthetics. Anesthesiology 2004; 100: 707-21 (Pubitemid 38268893)
23. Hausenloy DJ, Yellon DM. Reperfusion injury salvage kinase signalling: taking a RISK for cardioprotection. Heart Fail Rev 2007; 12: 217-34 (Pubitemid 350176695)
24. Zweier JL, Flaherty JT, Weisfeldt ML. Direct measurement of free radical generation following reperfusion of ischemic myocardium. Proc Natl Acad Sci USA 1987; 84: 1404-7 (Pubitemid 17027362)
25. Ambrosio G, Zweier JL, Duilio C, et al. Evidence that mitochondrial respiration is a source of potentially toxic oxygen free radicals in intact rabbit hearts subjected to ischemia and reflow. J Biol Chem 1993; 268: 18532-41 (Pubitemid 23273786)
26. Xia Z, Godin DV, Chang TK, Ansley DM. Dose-dependent protection of cardiac function by propofol during ischemia and early reperfusion in rats: effects on 15-F2t-isoprostane formation. Can J Physiol Pharmacol 2003; 81: 14-21 (Pubitemid 36407969)
27. Shao H, Li J, Zhou Y, et al. Dose-dependent protective effect of propofol against mitochondrial dysfunction in ischaemic/reperfused rat heart: role of cardiolipin. Br J Pharmacol 2008; 153: 1641-9 (Pubitemid 351536002)
28. Wang B, Shravah J, Luo H, Raedschelders K, Chen DD, Ansley DM. Propofol protects against hydrogen peroxide-induced injury in cardiac H9c2 cells via Akt activation and Bcl-2 up-regulation. Biochem Biophys Res Commun 2009; 389: 105-11
29. Jugdutt BI. Ventricular remodeling after infarction and the extracellular collagen matrix: when is enough enough? Circulation 2003; 108: 1395-403 (Pubitemid 37174420)
30. Rutschow S, Li J, Schultheiss HP, Pauschinger M. Myocardial proteases and matrix remodeling in inflammatory heart disease. Cardiovasc Res 2006; 69: 646-56 (Pubitemid 43139727)
31. Shan X, Xu X, Cao B, et al. Transcription factor GATA-4 is involved in erythropoietin-induced cardioprotection against myocardial ischemia/reperfusion injury. Int J Cardiol 2009; 134: 384-92
32. Wojciak-Stothard B, Tsang LY,Haworth SG. Rac and Rho play opposing roles in the regulation of hypoxia/reoxygenation-induced permeability changes in pulmonary artery endothelial cells. Am J Physiol Lung Cell Mol Physiol 2005; 288: L749-60 (Pubitemid 40404144)
33. Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling-concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol 2000; 35: 569-82 (Pubitemid 30167013)
34. Van Linthout S, Seeland U, Riad A, et al. Reduced MMP-2 activity contributes to cardiac fibrosis in experimental diabetic cardiomyopathy. Basic Res Cardiol 2008; 103: 319-27
35. Asbun J, Manso AM, Villarreal FJ. Profibrotic influence of high glucose concentration on cardiac fibroblast functions: effects of losartan and vitamin E. Am J Physiol Heart Circ Physiol 2005; 288: H227-34 (Pubitemid 40023851)
36. Cheng TH, Leung YM, Cheung CW, Chen CH, Chen YL, Wong KL. Propofol depresses angiotensin II-induced cell proliferation in rat cardiac fibroblasts. Anesthesiology 2010; 112: 108-18
37. Shirvaikar N, Marquez-Curtis LA, Shaw AR, Turner AR, Janowska-Wieczorek A. MT1-MMP Association with membrane lipid rafts facilitates G-CSF-induced hematopoietic stem/progenitor cell mobilization. Exp Hematol 2010; 38: 823-35
38. Hattori N, Mochizuki S, Kishi K, et al. MMP-13 plays a role in keratinocyte migration, angiogenesis, and contraction in mouse skin wound healing. Am J Pathol 2009; 175: 533-46
39. Brauer PR. MMPs-role in cardiovascular development and disease. Front Biosci 2006; 11: 447-78
40. Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010; 141: 52-67